News Release

Computer model predicts how drugs affect heart rhythm

UC Davis researchers develop an easy pre-clinical test of cardiac safety

Peer-Reviewed Publication

University of California - Davis Health

Clancy and Research Team

image: Colleen E. Clancy with Pei-Chi Yang and Kevin DeMarco of her research team (from left to right). view more 

Credit: Copyright UC Regents

UC Davis Health researchers have developed a computer model to screen drugs for unintended cardiac side effects, especially arrhythmia risk.

Published in Circulation Research, the study was led by Colleen E. Clancy, professor of physiology and membrane biology, and Igor Vorobyov, assistant professor of physiology and membrane biology.

Clancy is a recognized leader in using high-performance computing to understand electrical changes in the heart.

"One main reason for a drug being removed from the market is potentially life-threatening arrhythmias," Clancy said. "Even drugs developed to treat arrhythmia have ended up actually causing them."

The problem, according to Clancy, is that there is no easy way to preview how a drug interacts with hERG-encoded potassium channels essential to normal heart rhythm.

"So far there has been no surefire way to determine which drugs will be therapeutic and which will harmful," Clancy said. "What we have shown is that we can now make this determination starting from the chemical structure of a drug and then predicting its impact on the heart rhythm."

Using a drug's chemical formula, the computer model reveals how that drug specifically interacts with hERG channels as well as cardiac cells and tissue. The outcomes can then be validated with comparisons to clinical data from electrocardiogram (ECG) results of patients. For the study, the researchers validated the model with ECGs of patients taking two drugs known to interact with hERG channels -- one with a strong safety profile and another known to increase arrhythmias. The results proved the accuracy of the model.

Clancy envisions the model will offer an essential pre-market test of cardiac drug safety. That test could ultimately be used for other organ systems such as the liver and brain.

"Every new drug needs to go through a screening for cardiac toxicity, and this could be an important first step to suggesting harm or safety before moving on to more expensive and extensive testing," Clancy said.


Clancy and Vorobyov's colleagues on the study were Pei-Chi Yang, Kevin DeMarco, Parya Aghasafari, Mao-Tsuen Jeng, John R.D. Dawson and Vladimir Yarov-Yarovoy of UC Davis; Slava Bekker of American River College; and Sergei Y. Noskov of the University of Calgary.

Their work was funded by the National Institutes of Health, Canadian Institutes of Health Research, American Heart Association, UC Davis Department of Physiology and Membrane Biology Research Partnership Fund, Team-based Grant in Physiology, Biomolecular Simulation Time Allocations on Anton 2 at Pittsburgh Supercomputing Center, XSEDE Research Allocations, Compute Canada Resource Allocation Award and NCSA Blue Waters Broadening Participation Allocation.

A copy of "A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm" is available online.

More information about UC Davis Health, including its Department of Physiology and Membrane Biology, is at

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.